Nephroprotective effects of sodium-glucose linked transporter-2 inhibitors
- Autores: Daminov B.T.1,2, Abdullaev S.S1, Sharapov O.N1,2
-
Afiliações:
- Tashkent Pediatric Medical Institute
- Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation
- Edição: Volume 12, Nº 4 (2020)
- Páginas: 75-79
- Seção: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273392
- DOI: https://doi.org/10.18565/nephrology.2020.4.75-79
- ID: 273392
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Sobre autores
B. Daminov
Tashkent Pediatric Medical Institute; Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation
Email: nefrologiya2019@mail.ru
Dr. Sci. (Med.), Professor at the Department of Faculty Internal Diseases, Occupational Pathology, MFT, Hospital Internal Diseases and PID, Tashkent Pediatric Medical Institute; Director of the Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation
Sh. Abdullaev
Tashkent Pediatric Medical Institute
Email: dr.sherzod@rambler.ru
Dr. Sci. (Med.), Associate Professor at the Department of Faculty Internal Diseases, Occupational Pathology, MFT, Hospital Internal Diseases and PID, Tashkent Pediatric Medical Institute
O. Sharapov
Tashkent Pediatric Medical Institute; Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation
Email: olimkhon@gmail.com
Doctoral Student at the Department of Faculty Internal Diseases, Occupational Pathology, MFT, Hospital Internal Diseases and PID, Tashkent Pediatric Medical Institute; Nephrologist at the Republican Specialized Scientific and Practical Medical Center of Nephrology and Kidney Transplantation
Bibliografia
- Thrasher J. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. Am. J. Cardiol. 2017;120(1):S4-S16. Doi: 10.1016/j. amjcard.2017.05.009.
- Демидова Т.Ю. Сосудистые осложнения сахарного диабета 2 типа за гранью гликемического контроля. Сахарный диабет. 2016;3:111-116.
- Bonadonna R.C., Borghi C., Consoli A., Volpe M. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. Nutr. Metab. Cardiovasc. Dis. 2016;26:759-766. doi: 10.1016/j.numecd.2016.05.007.
- Satoh H. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control. Diabetol. Int. 2018;9:212-214. doi: 10.1007/s1334018-0367-x.
- Maltese G, Abou-Saleh A., Gnudi L., Karalliedde J. Preventing diabetic renal disease: the potential reno-protective effects of SGLT2 inhibitors. Br. J. Diabetes Vasc. Dis. 2015;15:114-118. doi: 10.15277/bjdvd.2015.031.
- Prie D. Familial renal glycosuria and modifications of glucose renal excretion. Diabetes Metab. 2014;40(1):S12-S16. Doi: 10.1016/ S1262-3636(14)72690-4.
- Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med. 2015;66:255-270. doi: 10.1146/annurev-med-051013-110046.
- Maldonado-Cervantes M.I., Galicia O.G., Moreno-Jaime B. et al. Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-a in LLC-PK1 cells. J. Physiol. Biochem. 2012;68:411-420. doi: 10.1007/s13105-012-0153-3.
- Panchapakesan U, Pegg K., Gross S. et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells - renoprotection in diabetic nephropathy? PLoS One. 2013;8:e54442. doi: 10.1371/journal.pone.0054442.
- Vallon V., Thomson S.C. Targeting renal glucose reabsorption to treat hypergly-caemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215-225. doi: 10.1007/s00125-016-4157-3.
- Gembardt F., Bartaun C., Jarzebska N. et al. The SGLT2 inhibitor empa-gliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am. J. Physiol. Renal Physiol. 2014;307:F317-F325. doi: 10.1152/ajprenal.00145.2014.
- Ojima A., Matsui T., Nishino Y. et al. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Horm. Metab. Res. 2015;47:686-692. doi: 10.1055/s-0034-1395609.
- Terami N., Ogawa D., Tachibana H. et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;24:e100777. doi: 10.1371/journal.pone.0100777.
- Hatanaka T., Ogawa D., Tachibana H. et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol. Res. Perspect. 2016;4:e00239. Doi: 10.1002/ prp2.239.
- Nagata T., Fukuzawa T., Takeda M. et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice // Br. J. Pharmacol 2013. Vol. 170. P. 519-531. doi: 10.1111/bph.12269.
- Kawanami D., Matoba K., Takeda Y. et al. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. Int. J. Mol. Sci. 2017;18:E1083. doi: 10.3390/ijms18051083.
- Jaikumkao K., Pongchaidecha A., Chueakula N. et al. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model // Biochim. Biophys. Acta. 2018;1864:2021-2033. doi: 10.1016/j.bbadis.2018.03.017.
- Kojima N., Williams J.M., Slaughter T.N. et al. Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats. Physiol. Rep. 2015;3:e12436. doi: 10.14814/phy2.12436.
- Li L., Konishi Y., Morikawa T. et al. Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats. J. Pharm Sci. 2018;137:220-223. doi: 10.1016/j.jphs.2017.10.006.
- Zhang Y, Thai K., Kepecs D.M., Gilbert R.E. Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS ONE. 2016;11:e0144640. doi: 10.1371/journal.pone.0144640.
- Tahara A., Takasu T. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. Eur. J. Pharmacol. 2018;830:68-75. doi: 10.1016/j.ejphar.2018.04.024.
- Ma Q, Steiger S, Anders H.J. Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Physiol. Rep. 2017;5:e13228. doi: 10.14814/phy2.13228.
- Chang Y.-K., Choi H, Jeong J.Y. et al. Dapagliflozin, SGLT2 Inhibitor, attenuates renal ischemia-reperfusion injury. PLoS ONE. 2016;11:e0158810. doi: 10.1371/journal.pone.0158810.
- Zapata-Morales J.R., Galicia-Cruz O.G., Franco M., Morales F.M. Hypoxia-inducible factor-1a (HIF-1a) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia. J. Biol. Chem. 2014;289:346-357. doi: 10.1074/jbc. M113.526814.
- Shimazu T., Hirschey M.D., Newman J. et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339:211-214. doi: 10.1126/science.1227166.
- Mudaliar S., Alloju S., Henry R.R. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016;39:1115-1122. Doi: 10.2337/ dc16-0542.
- Perkovic V., de Zeeuw D., Mahaffey K.W. et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691-704. Doi: 10.1016/ S2213-8587(18)30141-4.
- Wiviott S.D., Raz I., Bonaca M.P. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2018. Nov 10. [Epub ahead of print]. doi: 10.1056/NEJMoa1812389.
- Clegg L.E., Heerspink H.J.L., Penland R.C. et al. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. Diabetes Care. 2019;42:318-326. Doi: 10.2337/ dc18-1871.
- Tang H., Li D., Zhang J. et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 2017;19:1106-1115. doi: 10.1111/dom.12917
- Cherney D.Z., Perkins B.A., Soleymanlou N. et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587-597. Doi: 10.1161/ CIRCULA TIONAHA.113.005081.
- Gomez D.M. Evaluation of renal resistances, with special reference to changes in essential hypertension. J. Clin. Invest. 1951;30:1143-1155.
- Skrtic M., Yang G.K., Perkins B.A. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014;57:2599-2602. doi: 10.1007/s00125-014-3396-4.
- Dekkers C.C.J., Petrykiv S., Laverman G.D. et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018;2:1988-1993. doi: 10.1111/dom.13301.
- Fioretto P., Del Prato S., Buse J.B. et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes. Metab. 2018;20:2532-2540. doi: 10.1111/dom.13413.
- Petrykiv S., Sjostrom C.D., Greasley P.J. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. Clin. J. Am. Soc. Nephrol. 2017;12:751-759. doi: 10.2215/CJN.10180916.
- U. S. National Library of Medicine Clinical Trials Database. URL: https:// clinicaltrials.gov.